# Kala Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kala-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.kalarx.com
- Total disclosed funding: $105M
- Latest round: Series C (Apr 13, 2016)
- Investors on record: 12

## About

Kala Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare and serious eye diseases, aiming to improve patient outcomes through its advanced treatment options.Kala Pharmaceuticals, Inc., founded in 2009 and headquartered in Waltham, US, specializes in ophthalmic therapies. The company transitioned its business model after selling its previously commercialized products to Alcon Inc. in July 2022. The firm has undergone 11 total deals, with its most recent funding round being a Private Placement/Follow on on November 28, 2022, raising USD 6.00 mn, bringing the total amount raised to USD 6.00 mn. The company was founded by Justin Hanes, who has a history in biotechnology and entrepreneurship, while Mark Iwicki serves as the CEO.Kala Pharmaceuticals specializes in innovative therapies targeting rare and serious eye diseases. Its flagship product, KPI-012, is in Phase 2b clinical trials for persistent corneal epithelial defect (PCED), and is also being evaluated for other ocular conditions. Furthermore, the company is developing an intravitreal therapy in preclinical stages, aimed at inherited retinal degenerations and other back-of-the-eye diseases. Kala's products are primarily distributed through healthcare providers, including ophthalmologists and hospitals, reaching a global market where their therapies can notably influence patient outcomes.In 2022, Kala Pharmaceuticals reported a revenue of USD 3.89 mn, alongside an EBITDA of -USD 40.72 mn. The firm has shifted its revenue model following the sale of previous products, focusing on the commercialization of specialized ophthalmic therapies.Kala Pharmaceuticals plans to utilize the proceeds from the recent funding to advance the clinical development of KPI-012 for treating PCED. They also aim to explore new geographic markets, although specific regions have not been disclosed. This development is a part of the company's strategy to enhance its product pipeline following a notable funding deal on November 28, 2022, where USD 6.00 mn was raised to support these initiatives.

## Funding rounds

- Series C, Apr 13, 2016, $68M — OrbiMed Advisors, Polaris Partners, Vivo Capital, Wellington Management, Longitude Capital, Lux Capital, CAM Capital, Crown Venture Funds, RA Capital Management
- Series B, Apr 16, 2014, $23M — Polaris Partners, Third Rock Ventures, Ysios Capital Partners, Lux Capital, Crown Venture Funds
- Series A, Feb 14, 2013, $5.8M — Polaris Partners, Third Rock Ventures, Lux Capital, Crown Venture Funds
- Seed, Feb 29, 2012, $6.2M — Lighthouse Capital Partners, Polaris Partners, Third Rock Ventures, Lux Capital
- Seed, Oct 26, 2010, $3M — Polaris Partners, Third Rock Ventures, Lux Capital

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A, Series B, Series C
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Seed, Series A, Series B
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Seed, Series A, Series B, Series C
- Lighthouse Capital Partners — Seed
- Crown Venture Funds — Series A, Series B, Series C
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- CAM Capital — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C